Taub Institute
Investigator
Lawrence Honig, MD, PhD
Email
lh456@cumc.columbia.edu
Lawrence Honig, MD, Ph.D., is a Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons (New York, NY), in the Department of Neurology (Division of Aging and Dementia), Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the Gertrude H. Sergievsky Center. He is Director of the Clinical Core of the Alzheimer's Disease Research Center at Columbia University.

Dr. Honig obtained his MD medical degree from the University of Miami (Miami, Florida), and his Ph.D. from the University of California at Berkeley (Berkeley, California). He underwent a postgraduate internship in Medicine and residency in Neurology training at Stanford University Medical Center (California). He served on the faculty of the Neurology departments at Stanford University Medical Center, and then at the University of Texas Southwestern Medical Center in Dallas, prior to his arrival at Columbia University in the year 2000. His research interests are in Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Dementia, Creutzfeldt-Jakob disease, and other disorders of nervous system aging and degeneration. In addition to directing the Clinical Core of the Alzheimer's Disease Research Center at Columbia University, he conducts a number of clinical drug study trials, and also engages in clinical patient care at NewYork-Presbyterian Hospital and at the Lucy G. Moses Center for Memory and Behavioral Disorders, in the Neurological Institute.


Clinical Studies Managed By This Investigator:
Condition Study Title
Alzheimer's Disease [ CLOSED ] A study assessing the safety and effectiveness of study drug Crenezumab in patients with mild to moderate Alzheimer's Disease
Alzheimer's Disease [ CLOSED ] A study for patients with early Alzheimer's Disease using study drug AZD3293
Alzheimer's Disease [ CLOSED ] A study for patients with Progressive Supranuclear Palsy (PCP) using study drug C2N-8E12
Neurological Disorders [ CLOSED ] A study for patients with Progressive Supranuclear Palsy using study drug BMS-986168
Alzheimer's Disease [ CLOSED ] A study for patients with Alzheimer's Disease using study drug azeliragon (TTP488)
Alzheimer's Disease [ CLOSED ] A study for patients with Alzheimer's disease using study drug crenezumab
Alzheimer's Disease [ CLOSED ] A study for patients with dementia using study drug RVT-101
Neurological Disorders [ CLOSED ] A study of safety and efficacy of IV BMS-986168 in patients with Progressive Supranuclear Palsy.
Alzheimer's Disease [ CLOSED ] Magnetic Resonance Spectroscopy (MRS) to assess progression of Alzheimer Disease (AD)
Alzheimer's Disease [ CLOSED ] MissionAD1: A 24-month Efficacy and Safety Study in Subjects with Early Alzheimer's Disease
Alzheimer's Disease [ CLOSED ] Study of New Drug in Patients with Cognitive Impairment or Mild Alzheimer's Disease
Neuromuscular [ CLOSED ] Study of Drug in Patients with Progressive Supranuclear Palsy
Alzheimer's Disease [ CLOSED ] Efficacy and Safety Study of Drug (MTAU9937A) in Patients with Alzheimer's Disease Preclinical-to-Mild or Moderate Alzheimer's Disease
Alzheimer's Disease [ CLOSED ] Study of Posiphen in Subjects with Early Alzheimer's Disease (AD) DISCOVER
Alzheimer's Disease [ CLOSED ] Study of Gantenerumab in Subjects with Early Alzheimer's Disease (Prodromal to Mild)
Dementia [ CLOSED ] Study of E2027 in Subjects with Lewy Body Dementia (LBD) (DELPHIA)
Alzheimer's Disease [ CLOSED ] Study of AL002 for Patients with Early Alzheimers Disease
Dementia Study of CT1812 in Patients with Dementia with Lewy Bodies (DLB)
Alzheimer's Disease New IDEAS: Brain Imaging Study for Memory Loss
Dementia New IDEAS: Brain Imaging Study for Memory Loss